Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
New Money but pummeled, this is all they could raise--->>>Aleafia Health Announces Closing of $10 Million Credit Facility
High interest and dilution just so they can keep the lights on. This is bad dilution. Bummer. - FUNMAN
Credit Facility provides financial capacity to pursue accretive growth opportunities
New debt lender increases financial flexibility with new source of capital
Improves liquidity by growing cash and marketable securities balance to $25 million
TORONTO, August 23, 2021 – Aleafia Health Inc. (TSX: AH, OTCQX: ALEAF) (“Aleafia Health” or the “Company”), a leader in cannabis wellness products and services, is pleased to announce the closing of a $10 million senior secured term (non-revolving) credit facility (the “Credit Facility”).
“This Credit Facility provides us with greater financial flexibility to pursue strategic opportunities and continue the robust sales growth realized during our most recent quarter. This transaction improves our capital structure and provides a lower cost of capital that we believe directly benefits our shareholders,” said Aleafia Health CEO Geoffrey Benic. “Our sales momentum across multiple adult-use product categories, continued scaling of our medical cannabis ecosystem, and the near-term harvest of our largest outdoor cannabis crop to date sets the stage for a strong second half of 2021.”
The full amount of the Credit Facility was drawn down by the Company on closing. The Credit Facility carries a 12-month term, with an option for early repayment, and accrues interest at a rate of 12% per annum, with the interest and principal amounts due upon maturity. The outstanding amount of the Credit Facility together with accrued and unpaid interest thereon, may be repaid by the Company at any time and also includes certain mandatory prepayment obligations upon certain specified incurrences. The Credit Facility is secured by first lien mortgages on the Paris, Ontario and Grimsby, Ontario production facilities.
As partial consideration for the Credit Facility, the Company has granted to the lender 1,000,000 common share purchase warrants (the “Warrants”) of the Company. Each Warrant entitles the holder thereof to acquire one common share (each, a “Warrant Share”) in the capital of the Company at an exercise price of $0.32, subject to adjustment in certain circumstances, until August 20, 2023. The Warrants vest in equal instalments of 250,000 Warrants commencing on November 20, 2021, and subsequently every three (3) months thereafter, subject to adjustment in certain circumstances. The Warrants are not transferable other than to affiliates of the lender.
The Toronto Stock Exchange has conditionally approved the listing of the Warrant Shares issuable on the due exercise of the Warrants. The Warrants and the Warrants Shares are subject to a statutory holder period in accordance with applicable securities laws.
The net proceeds from the Credit Facility are expected to be used to support accretive growth initiatives, including improved product availability in the adult-use business, accelerating onboarding of new employer relationships under the exclusive Unifor agreement, operational efficiency enhancements on the production lines at its manufacturing facility in Paris, Ontario, and for other general corporate purposes.
For Investor & Media Relations:
Nicholas Bergamini, VP Investor Relations
1-833-879-2533
IR@AleafiaHealth.com
LEARN MORE:www.AleafiaHealth.com
About Aleafia Health:
Aleafia Health is a vertically integrated and federally licensed Canadian cannabis company offering cannabis health and wellness services and products in Canada. The Company has developed an international footprint, with subsidiaries or investments in German and Australian medical cannabis companies and has products available in both markets. The Company owns and operates a virtual network of medical cannabis clinics staffed by physicians and nurse practitioners who have seen over 75,000 patients to date.
Aleafia Health owns three licensed cannabis production facilities and operates a strategically located distribution centre all in the province of Ontario, including the first large-scale, legal outdoor cultivation facility in Canadian history. The Company produces a diverse portfolio of cannabis derivative products including oils, capsules, edibles, sublingual strips, and vapes, for sale in Canada in the medical and adult-use markets, and in select international jurisdictions.
Forward Looking Information
This news release contains forward-looking information within the meaning of applicable Canadian and United States securities laws. Often, but not always, forward-looking information can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes” or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Specific forward-looking information contained in this release includes information relating, but not limited, to the Credit Facility, including the use of the net proceeds from the Credit Facility, and the Warrants. Forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company or its subsidiaries to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained in this news release. Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information, including risks contained in the Company’s annual information form filed with Canadian securities regulators available on the Company’s SEDAR profile at www.sedar.com. Although the Company believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information and no assurance can be given that such events will occur in the disclosed time frames or at all. The forward-looking information included in this news release are made as of the date of this news release and the Company does not undertake any obligation to publicly update such forward-looking information to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
Canadians have been out-buying themselves in legal weed this year, with another record set in June for retail cannabis sales.
On Friday, Statistics Canada released preliminary retail sales data, which shows a monthly increase of 1.7 per cent to $318.7 million. This is the fourth consecutive month the country hit record weed sales.
The daily spending average for June is about $10.6 million, and Canada could surpass $3.87 billion in weed sales this year.
Canada’s overall retail sales increased 4.2 per cent in June, primarily led by higher sales at clothing stores. Six provinces saw sales go up, with Ontario and Nova Scotia leading the pack at 9.8 per cent and 16.3 per cent respectively.
Weed sales have also gone up in those two provinces.
Nova Scotia’s sales shot up 10.5 per cent to $8.2 million, the largest jump of any province.
Ontario’s sales rose 8 per cent to $120.1 million, while Ottawa leaped 13.3 per cent to $12.1 million. Toronto’s $43.7 million represents a 5 per cent increase.
Canada’s most populous province has continued to add more retail stores, reaching more than 1,000 as of Friday.
Ontario Cannabis Store @ONCannabisStore
Aug 20 You can now shop at over 1000 Authorized Cannabis Retailers across Ontario, owned and operated by your local buds. Find a store near you: https://bit.ly/2GZSgh2
Large markets dip while weed sales climb in Maritimes and Prairies Of the four largest weed markets in Canada, Ontario is the only one to bring in higher sales in June.
Alberta’s sales dropped 4.4 per cent to $57.1 million, and Quebec dipped 0.7 per cent to $49.2 million.
Both provinces had cannabis sales steadily increase for most of the year — with the exception of February — before dipping in June.
Sales had been climbing for three months in British Columbia before dropping 4.1 per cent to $44.5 million in June. Vancouver’s sales decreased by 1.4 per cent to $14.4 million. A total of 371 licences have been issued in B.C. so far.
Saskatchewan sold $13 million, up 0.7 per cent from May, and Manitoba’s sales went up 2 per cent to $12.1 million.
It seems the Maritime provinces are faring better in June than the previous month as well.
In addition to improved sales in Nova Scotia, New Brunswick’s went up 3.4 per cent to $6.6 million. Newfoundland and Labrador saw a similar increase of 3.8 per cent to $4.9 million.
Sales for P.E.I and the Yukon haven’t been provided by StatsCan since March.
There weren’t any June numbers for the Northwest Territories either. Nunavut hasn’t had available sales data and currently only has one store.
Canada retail sales data from May has been revised slightly to $313.18 million.
We are in a very unique and almost secret position here. The industry is forced to stay on the fringes. Away from institutional access. The only ones here with us are the hedge funds who love to play their short games here in otc land. The instant this company shows its value they will turn into longs. Noting has changed in the company’s fundamentals. Their prospects are incredible and nobody seems to understand the situation. I am good with it until I can buy more lol!
One news item I missed while camping at Lake George--->>>Aleafia Health Reports Strong 2021 Second Quarter Financial Results with 53% Sequential Increase in Cannabis Net Revenue
IMO, measured against a crappy prior Q, the percentage gain is terrific. In real numbers, we are waiting on the Q3 harvest to really determine if Aleafia has what it takes or is just another cannabis also-ran in need of finding a buyer, or shuttering the doors. Compared to MediPharm which appears to be a completely failed cannabis investment, Aleafia does seem to possess potential life. Q3 and Q4 are more critical than ever before.
* Adult-use cannabis net revenue increased 87% compared to the prior quarter
* Medical cannabis net revenue increased 23% compared to the prior quarter
* 13 additional product SKUs released across multiple product formats For the first time, medical cannabis product was made available for sale in Germany
* Commenced onboarding of medical cannabis patients through exclusive partnership with Unifor (Gee, a number here would be nice. Are there 5, 10, 100 or 1,000 patients? Is it for real, or is it a joke?)
* Maintained strong adjusted gross margin on cannabis net revenue of 49% (This is a pretty high margin compared to the industry in the USA and Canada. Kudo's to Aleafia for cost containment.)
TORONTO – August 12, 2021 – Aleafia Health Inc. (TSX: AH, OTCQX: ALEAF) (“Aleafia Health” or the “Company”) is pleased to report its financial results for the three and six months ended June 30th, 2021.
“This quarter clearly demonstrates the success of our expanded product portfolio, with strong sequential growth across all sales channels and a shift towards a more balanced mix with sizable contributions from both the medical and adult-use cannabis markets. Credit goes to our management team and employees for delivering record adult-use, and medical cannabis revenue this quarter,” said Aleafia Health CEO Geoffrey Benic. “Despite industry-wide price compression, we have maintained robust gross margins on cannabis revenue when compared to other Canadian licensed producers, based on most recently reported quarterly results. This was achieved through our twin pillars of low-cost cultivation and high-quality, differentiated cannabis derivative formats.
“With an already well-established line of cannabis wellness products, we were delighted to see sequential revenue increases driven by our newly launched dried flower and pre-roll portfolio. Gaining access to the German medical cannabis market marks an important milestone that, with continued successful shipments, can contribute revenue growth and gross margin expansion. The development of our domestic medical cannabis channel and broader patient ecosystem are well positioned as we continue the ramp-up of our exclusive partnership with Unifor, Canada’s largest private sector union.
“Lastly, we were able to complete planting across 86 acres outdoors, over a full a month earlier than last year, laying the groundwork for the 2021 harvest. Outdoor cultivation remains a core competitive advantage both in cost and scale, for our dried flower portfolio and as input for cannabis product derivative formats. Likewise, it will allow us to be opportunistic in securing bulk wholesale revenue later this year and into early 2022.”
($,000s) Three months ended Six months ended Jun 30, 2021 Jun 30, 2020 Jun 30, 2021 Jun 30, 2020 Net revenue 10,672 9,775 17,738 24,371 Cannabis net revenue(1)(3) 9,583 8,995 15,828 22,722 Adjusted gross profit before fair value (“FV”) adjustments on net cannabis revenue(1)(3) 4,740 2,962 8,442 14,636 Adjusted gross margin before FV adjustments on net cannabis revenue(1)(3) 49% 33% 53% 64% Adjusted EBITDA(1)(2) (3,339) 3,065 (6,372) 9,829 Net loss (36) (4,021) (11,284) (10,176) 1. See “Cautionary Statements Regarding Certain non-IFRS Measures” section of associated MD&A for term definition. 2. See “Adjusted EBITDA” section of associated MD&A for reconciliation to IFRS equivalent. 3. See “Revenue” section of associated MD&A for reconciliation to IFRS equivalent.
OPERATIONAL RESULTS
($,000s, except operational results) Three months ended % Change Jun 30, 2021 Mar 31, 2021 Jun 30, 2020 Q/Q Y/Y Net medical cannabis revenue(1)(2) 3,266 2,657 1,959 23% 67% Net adult-use cannabis revenue(1)(2) 3,217 1,722 870 87% 270% Net bulk wholesale cannabis revenue(1)(2) 3,100 1,866 6,166 66% -50% Cannabis net revenue(1)(2) 9,583 6,245 8,995 53% 7% Net clinic revenue 1,089 821 780 33% 40% Active, registered patients 18,067 17,637 13,285 2% 36% Average net selling price per gram of medical cannabis(1) $7.25 $8.46 $7.87 -14% -8% Average net selling price per gram of adult-use cannabis(1) $5.29 $4.89 $4.81 8% 10% Average net selling price per gram of bulk wholesale cannabis(1) $0.46 $0.75 $2.92 -39% -84% Adjusted gross margin before FV adjustments on medical cannabis net revenue(1)(2) 41% 53% 41% -12% 0% Adjusted gross margin before FV adjustments on adult-use cannabis net revenue(1)(2) 47% 56% 37% -9% 10% Adjusted gross margin before FV adjustments on wholesale cannabis net revenue(1)(2) 60% 71% 30% -11% 30% Gross margin on clinic net revenue(1)(2) 61% 20% 69% 41% -8% Kilograms sold 7,811 3,155 2,545 148% 207% 1. See “Cautionary Statements Regarding Certain non-IFRS Measures” section of associated MD&A for term definition. 2. See associated MD&A for reconciliation to IFRS equivalent.
* During the three months ended June 30, 2021 (“Q2 2021”) cannabis net revenue was $9.6 million, an increase of 53% over the previous quarter.
* The sequential increase was due to increases in the sale of cannabis across the adult-use, medical and bulk wholesale sales channels.
* Medical cannabis net revenue for Q2 2021 was $3.3 million, a 23% and 67% increase over the previous and prior year’s quarter respectively, due to improved product offerings and increased international medical cannabis sales.
* Net adult-use cannabis revenue for Q2 2021 was $3.2 million, an increase of 87% over the previous quarter and 270% over the prior year’s quarter. The sequential increase was primarily due to greater product availability, including the launch of new product formats and SKUs.
* Net bulk wholesale revenue received from sales to cannabis licensed producers was $3.1 million, compared to $1.9 million and $6.2 million in the previous and prior year’s quarter, respectively. Bulk wholesale was up over Q1 2021, but lower than the prior year’s quarter, primarily driven by dried flower allocation, which was redirected to the adult-use sales channel.
* Adjusted gross margin before FV adjustments on cannabis net revenue was 49%, compared to 59% and 33% in the previous and prior year’s quarters, respectively. The sequential decline in gross margin percentage was primarily due to industry-wide price compression, which was reflected in a lower net revenue per gram equivalent sold.
* Adjusted EBITDA for Q2 2021 was a loss of $3.3 million, compared to a profit of $3.1 million in the prior year’s quarter. The decline over the prior year’s quarter was primarily due to increases in wages & benefits expense, partially offset by increased gross profit from the sale of cannabis.
* Net loss for the three months ended June 30, 2021 was $36,000, compared to a net loss of $4.0 million over the prior year’s quarter. The improvement in net loss over the prior year’s quarter is primarily due to improved gross profit, a $12.1 million gain on the sale of certain clinic assets in the transaction with Myconic, partially offset by bad debt expense of $7.2 million.
PRODUCT LAUNCHES & KEY DEVELOPMENTS
Throughout the reporting period, the Company undertook an expansion of its cannabis brand and product portfolio, including differentiated formats and new SKUs in the important value flower and pre-roll categories
Exports to Germany & Australia: During Q2 2021, the Company announced dried flower grown at its Niagara greenhouse facility had been exported to Germany. Gaining access to Europe’s legal cannabis market is an important breakthrough for Aleafia Health. Shipments of medical cannabis products to Australia were also completed during the quarter.
Dried Flower & Pre-rolls: The Company has undertaken an expansion of its dried flower and pre-roll offering, which represents the first and third largest product categories in the Canadian cannabis market, respectively. These include a pre-roll line extension with 12 pre-rolls each of 0.35 grams, and larger format 14-gram flower and 10-gram milled flower pouches. Sales of these products and other new dried flower SKUs commenced during Q2 2021, under the newly launched brand Divvy.
Differentiated Wellness Products: During Q2 2021, the Company launched Lavender Fizz CBD bath bombs, and CBD Freshly Minted Roll-on, under its trailblazing wellness brand Noon & Night. The quarter also featured the launch of the Omega CBD Soft Gels which feature full-spectrum, single strain CBD extract, and are the first Canadian cannabis products to be suspended in fish oil containing omega-3.
Confectionary Edibles: The Company strengthened its edibles portfolio with Salted Caramel Pretzel Bites, which were launched under the Bogart’s Kitchen edibles brand.
Unifor Program: During the reporting period, the Company commenced providing medical cannabis products and services to unionized employees of the Ford Motor Company of Canada, through its exclusive partnership with Unifor, Canada’s largest private sector union.
2021 Outdoor Cultivation Season: On June 18, 2021, the Company completed planting across 86 acres at the Port Perry Facility outdoor cultivation site. The milestone was achieved a month earlier, and on a significantly larger scale, than the 2020 outdoor season, which yielded 31,200 kgs of dried flower, at a cost of $0.10 per gram to harvest.
SELECTED BALANCE SHEET INFORMATION
($,000s) Jun 30, 2021 Dec 31, 2020 Cash, cash equivalents, marketable securities 17,804 30,529 Current assets 71,055 82,923 Current liabilities 49,901 45,041 Working capital 21,154 37,882 Total assets 221,423 237,283 Total liabilities 54,866 83,062 Capitalization Lease liability 2,620 3,167 Convertible debt 33,931 56,802 Total debt 36,551 59,969 Total equity 166,557 154,221 Total capitalization 203,108 214,190 CONFERENCE CALL & WEBCAST
Date: August 12, 2021 Time: 9:30 a.m. ET USA/Canada Toll-Free Participant Call-in: (866) 679-9046; Passcode: 6096362 International Toll-Free Participant Call-in: (409) 217-8323; Passcode: 6096362
WEBCAST LINK
This conference call will be webcast live over the internet and can be accessed through the link provided. Audio of the call will be available to participants through both the conference call line and webcast; however, the presentation may only be viewed via the webcast. A replay of the call be viewed at any time via the link provided.
For Investor & Media Relations:
Nicholas Bergamini, VP Investor Relations 1-833-879-2533 IR@AleafiaHealth.com LEARN MORE: www.AleafiaHealth.com
I understand that the offer was never lower than my bid, but when a sell-at-the-market order is placed, how does it make any sense to fill that sell order at a bid lower than the highest bid? That’s trading thru the bid in my book. It’s the same thing as having an offer lower than the bid.
I would bet that the ask always stayed above your bid price of .291. Therefore, it was a "hit or miss" situation for you. You got over 1/2 the shares you wanted and some others were able to buy some shares at a bit lower price. Unfortunately, you don't have a leg to stand on if you were to contest it with your broker since your bid was lower than the ask.
I'll be camping at Lake George when they announce. - FUNMAN
TORONTO – August 4, 2021 – Aleafia Health Inc. (TSX: AH, OTCQX: ALEAF) (“Aleafia Health” or the “Company”) will announce its 2021 second quarter results on August 12, 2021 prior to market open. The Company will also host its earnings conference call the same day at 9:30 a.m. ET. The call will be hosted by CEO Geoffrey Benic and CFO Matt Sale.
CONFERENCE CALL & WEBCAST
Date: August 12, 2021 Time: 9:30 a.m. ET USA/Canada Toll-Free Participant Call-in: (866) 679-9046; Passcode: 6096362 International Toll-Free Participant Call-in: (409) 217-8323; Passcode: 6096362
WEBCAST LINK
This conference call will be webcast live over the internet and can be accessed through the link provided. Audio of the call will be available to participants through both the conference call line and webcast; however, the presentation may only be viewed via the webcast. Participants who miss the live call can view a replay at any time via the link provided.
For Investor & Media Relations:
Nicholas Bergamini, VP Investor Relations 1-833-879-2533 IR@AleafiaHealth.com LEARN MORE: www.AleafiaHealth.com
About Aleafia Health:
Aleafia Health is a vertically integrated and federally licensed Canadian cannabis company offering cannabis health and wellness services and products in Canada and with sales and operations in Australia and Germany. The Company operates medical clinics, education centres and production facilities for the production and sale of cannabis.
Aleafia Health owns four significant licensed cannabis production facilities, including the first large-scale, legal outdoor cultivation facility in Canadian history. The Company produces a diverse portfolio of commercially proven, high-margin derivative products including oils, capsules, edibles, sublingual strips, and vapes. Aleafia Health operates the largest national network of medical cannabis clinics and education centres staffed by MDs, nurse practitioners and educators and operates internationally in three continents.
Forward Looking Information
This news release contains forward-looking information within the meaning of applicable Canadian and United States securities laws. Often, but not always, forward-looking information can be identified by the use of words such as “plans”, “expects”, “estimates”, “intends”, “anticipates”, or “believes” or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company or its subsidiaries to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained in this news release. Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information, including risks contained in the Company’s annual information form filed with Canadian securities regulators available on the Company’s SEDAR profile at www.sedar.com. Although the Company believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information and no assurance can be given that such events will occur in the disclosed time frames or at all. The forward-looking information included in this news release are made as of the date of this news release and the Company does not undertake any obligation to publicly update such forward-looking information to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
TORONTO, July 29, 2021 – Aleafia Health Inc. (TSX: AH, OTCQX: ALEAF) (“Aleafia Health” or the “Company”) a global leader in cannabis wellness products and services, is pleased to announce the appointment of Mark J. Sandler as Chairman of its Board of Directors (the “Board”). He is the longest serving member of the Company’s board, which is composed entirely of independent directors, and chairs its Governance Committee.
Currently senior partner at Cooper, Sandler, Shime, & Bergman LLP, Mr. Sandler is a leading appellate and trial lawyer, as well as an adjudicator and mediator in regulatory matters, including securities litigation. He served three terms as an elected member of the Law Society of Ontario’s governing body.
“Aleafia Health is well positioned to continue on its growth trajectory of the last three years, from a pre-revenue startup to a leading global cannabis company,” said Mr. Sandler. “In supporting the objectives of the company, we will continue to prioritize strong corporate governance, and sustainable growth in the adult-use, medical and international markets.”
For Investor & Media Relations:
Nicholas Bergamini, VP Investor Relations
1-833-879-2533
IR@AleafiaHealth.com
LEARN MORE: www.AleafiaHealth.com
About Aleafia Health:
Aleafia Health is a vertically integrated and federally licensed Canadian cannabis company offering cannabis health and wellness services and products in Canada and with sales and operations in Australia and Germany. The Company operates medical clinics, education centres and production facilities for the production and sale of cannabis.
Aleafia Health owns four significant licensed cannabis production facilities, including the first large-scale, legal outdoor cultivation facility in Canadian history. The Company produces a diverse portfolio of commercially proven, high-margin derivative products including oils, capsules, edibles, sublingual strips, and vapes. Aleafia Health operates the largest national network of medical cannabis clinics and education centres staffed by MDs, nurse practitioners and educators and operates internationally in three continents.
Forward Looking Information
This news release contains forward-looking information within the meaning of applicable Canadian and United States securities laws. Often, but not always, forward-looking information can be identified by the use of words such as “plans”, “expects”, “estimates”, “intends”, “anticipates”, or “believes” or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company or its subsidiaries to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained in this news release. Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information, including risks contained in the Company’s annual information form filed with Canadian securities regulators available on the Company’s SEDAR profile at www.sedar.com. Although the Company believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information and no assurance can be given that such events will occur in the disclosed time frames or at all. The forward-looking information included in this news release are made as of the date of this news release and the Company does not undertake any obligation to publicly update such forward-looking information to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
The Company and Its Subsidiary KGK Science Have Also Completed the Pre-Qualification Audits of Its Canadian Facilities to Enable Clinical Trials in an Arrangement with Aleafia Health
VANCOUVER, British Columbia, July 28, 2021 (GLOBE NEWSWIRE) -- KetamineOne Capital Limited (“Ketamine One” or the “Company”) (NEO: MEDI) (OTC: KONEF) (Frankfurt: MY0), a company focused on consolidating medical clinics and becoming a North American leader in mental health treatments, is pleased to announce that its wholly-owned contract research organization (“CRO”), KGK Science Inc., (“KGK”) has recently achieved several milestones in its psychedelic research capabilities and significantly expanded its access to patients through further integration with Ketamine One.
Controlled Drugs and Substances Dealer’s Licence:
KGK recently applied for a controlled drugs and substances dealer’s licence under Canada’s Narcotic Control Regulations governing the possession, distribution, sale, clinical studies of and research and development of controlled substances, including Psilocybin, Psilocin, Ketamine, MDMA, LSD, DMT, Mescaline, Salvinorin A, Harmaline and Harmalol.
Subject to the approval of Health Canada, the licence will effectively enable KGK to offer a turn-key solution for third parties to conduct clinical trials involving psychedelic molecules, while also authorizing KGK to act as a centralized distributor for large, multi-location clinical trials.
Pre-Qualification of Canadian Facilities for Clinical Trials:
Additionally, Ketamine One has completed the pre-qualification audits of its Canadian clinics with KGK to prepare for the use of the Company’s facilities in future clinical trials. The audits will enable KGK to conduct clinical trials in the areas of psychedelics and nutraceuticals, among other substances of study. This direct access to patients and clinics is expected to differentiate KGK from other CROs by providing the opportunity to study patients with differing demographics across various populations, while also shortening recruitment timelines for studies.
The Company has been focused on a swift integration of the medical clinics that Ketamine One previously announced on May 7th as having been acquired from Canabo Medical Corporation, a wholly-owned subsidiary of Aleafia Health Inc. (TSX: AH) (“Aleafia”) together with its other recent acquisition of KGK announced on June 3rd.
Additionally, as previously announced on January 21, 2021, Unifor and Aleafia entered into an exclusive 10-year agreement to support union members, retirees and their eligible dependents that receive medical cannabis insurance coverage clinics through Unifor's collective bargaining agreements. To date, the clinic network has seen over 75,000 unique patients and has conducted extensive research in cannabinoid therapy as it relates to sleeping disorders, opioid reduction and other topics.
Management Commentary:
“Today’s announcements are further evidence of the synergies between our growing clinic network and our contract research offerings,” said Ketamine One’s Interim CEO, Adam Deffett. “KGK will now have the ability to utilize our clinic sites for future trials, gain access to a large patient database and, upon approval, have a narcotic dealers license.
Our goal is that these initiatives will also provide Ketamine One patients with breakthrough treatments through clinical trials and our clinical staff with experience and protocols needed for the eventual expansion of new treatments. We view this as a great opportunity to demonstrate their operational capabilities while also earning a new revenue stream from Ketamine One,” added Mr. Deffett.
General Research:
The Company has engaged General Research GmbH (“GR”) to increase its exposure to investors in Europe. The services agreement with GR has an aggregate cash cost of 40,000 Euros, has an initial term of two months, and such term may be extended for subsequent periods. GR will not receive any securities of the Company as compensation, and it does not currently own any securities of Ketamine One. Ketamine One and GR are unrelated and unaffiliated entities; GR is arm’s length to the Company.
ABOUT KETAMINE ONE
KetamineOne Capital Limited (formerly Myconic Capital Corp.) is a company focused on consolidating medical clinics and becoming a North American leader in mental health treatments. It is working to provide the critical infrastructure needed to develop and deliver breakthrough mental health treatments. Currently, Ketamine One has a network of 16 clinics across North America, with plans to further consolidate the highly fragmented industry. The recent addition of KGK Science Inc. as the Company’s contract research division also places the company at the forefront of premium clinical research based on its 23-year history and extensive experience in pharmaceuticals, cannabis, and the emerging psychedelic medicine industries. As a collective enterprise, Ketamine One is dedicated to helping solve the growing need for safe and accessible mental health therapy.
This news release contains forward-looking statements including but not limited to statements regarding the Company’s business, assets or investments, as well other statements that are not historical facts. Readers are cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are based will occur. By their nature, forward-looking statements involve numerous assumptions, known and unknown risks and uncertainties, both general and specific, that contribute to the possibility that the predictions, forecasts, projections and other forward-looking statements will not occur, which may cause actual performance and results in future periods to differ materially from any estimates or projections of future performance or results expressed or implied by such forward-looking statements. These assumptions, risks and uncertainties include, among other things, the state of the economy in general and capital markets in particular, investor interest in the business and future prospects of the Company.
The forward-looking statements contained in this news release are made as of the date of this news release. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities law. Additionally, the Company undertakes no obligation to comment on the expectations of, or statements made, by third parties in respect of the matters discussed above.
Diogenes, Let's hope someone gives a hoot. Moving forward introducing new brands is great, but without marketing, it's as if mgmt is just throwing the spaghetti at the wall and hoping it sticks as well as Grey Goose Vodka did, and they did a ton of marketing.
Better analogies are cigars and scotches. In an age where smoking is frowned upon it's tough to find a breakout success. Maybe Cohiba and Macanudo rings a bell with some people. Scotch brands are even more elusive. Maybe most people know of Jonnie Walker, but aficionados gravitate to single malts.
All I am saying is releasing great new strains that appeals to experienced cannabis aficionados isn't going to move the needle unless it's the "next Grey Goose".
Aleafia has to so more with social marketing. Other producers are doing it. Aleafia is pretty much ignoring brand building and creating demand.
I know there are advertising prohibitions, but other companies are doing it within the legal allowable parameters. Aleafia has to do more of it and get better at it.
Aleafia Health Launches Premium Cannabis Brand Nith & Grand
* Nith & Grand tailored to cannabis aficionados with discerning taste, and will feature craft flower and premium concentrates
* Initial launch features TF Pink Kush Live Resin vape cartridges
* Strengthened product portfolio contributing to meaningful quarterly sales growth across all sales channels
TORONTO, July 19, 2021 – Aleafia Health Inc. (TSX: AH, OTCQX: ALEAF) (“Aleafia Health” or the “Company”) is pleased to announce the launch of its premium cannabis brand Nith & Grand.
Featuring hang dried, hand trimmed, small batch dried flower, and premium concentrates, Nith & Grand appeals to experienced cannabis aficionados.
The initial launch features TF Pink Kush Live Resin vape cartridges, which comprises a hydrocarbon extraction process utilizing fresh-frozen cannabis flower that preserves the strain’s natural flavour, aroma and terpene profile. The new product features the highly sought after and not yet widely available TF Pink Kush strain, and is now available in adult-use markets.
“Nith & Grand completes our highly differentiated brand portfolio, allowing us to reach the growing market for premium, craft cannabis products. With a collection of highly sought after cultivars and six years operating our craft cultivation facility in Paris, Ont., we are perfectly situated to delight cannabis connoisseurs,” said Aleafia Health CEO Geoffrey Benic.
“Aleafia Health can now boast one of the strongest and most diverse product portfolios in the Canadian cannabis industry. This along with scaling our production has directly led to strong sequential sales growth in the adult-use, wholesale, and medical sales channels, both domestically and internationally, in our most recent quarter.”
Nith & Grand’s namesake is a tribute to our product innovation facility’s home community of Paris, Ont., whose scenic downtown core is centred around the confluence of the Nith and Grand rivers.
For Investor & Media Relations:
Nicholas Bergamini, VP Investor Relations
1-833-879-2533
IR@AleafiaHealth.com
LEARN MORE: www.AleafiaHealth.com
About Aleafia Health:
Aleafia Health is a vertically integrated and federally licensed Canadian cannabis company offering cannabis health and wellness services and products in Canada and with sales and operations in Australia and Germany. The Company operates medical clinics, education centres and production facilities for the production and sale of cannabis.
Aleafia Health owns four significant licensed cannabis production facilities, including the first large-scale, legal outdoor cultivation facility in Canadian history. The Company produces a diverse portfolio of commercially proven, high-margin derivative products including oils, capsules, edibles, sublingual strips, and vapes. Aleafia Health operates the largest national network of medical cannabis clinics and education centres staffed by MDs, nurse practitioners and educators and operates internationally in three continents.
Forward Looking Information
This news release contains forward-looking information within the meaning of applicable Canadian and United States securities laws. Often, but not always, forward-looking information can be identified by the use of words such as “plans”, “expects”, “estimates”, “intends”, “anticipates”, or “believes” or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company or its subsidiaries to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained in this news release. Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information, including risks contained in the Company’s annual information form filed with Canadian securities regulators available on the Company’s SEDAR profile at www.sedar.com. Although the Company believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information and no assurance can be given that such events will occur in the disclosed time frames or at all. The forward-looking information included in this news release are made as of the date of this news release and the Company does not undertake any obligation to publicly update such forward-looking information to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
COVID-19 Literatura global sobre doença de coronavírus ??????? ?? (??) english français ??????? español português Notícias/Atualização/Ajuda
Busca Avançada
Pesquisar Home Pesquisa Cannabidiol Inhibits SARS-CoV-2 Replication and Promotes the Host Innate Immune Response Este artigo é um Preprint
Cannabidiol Inhibits SARS-CoV-2 Replication and Promotes the Host Innate Immune Response Dongbo Yang; Long Chi Nguyen; Vlad Nicolaescu; Thomas Best; Shaonong Chen; J. Brent Friesen; Nir Drayman; Adil Mohamed; Christopher Dann; Diane Silva; Haley Gula; Krysten A. Jones; J. Michael Millis; Bryan C. Dickinson; Savas Tay; Scott A. Oakes; Guido F. Pauli; David O. Meltzer; Glenn Randall; Marsha Rich Rosner. Preprint | bioRxiv | ID: ppbiorxiv-432967 ABSTRACT The rapid spread of COVID-19 underscores the need for new treatments. Here we report that cannabidiol (CBD), a compound produced by the cannabis plant, inhibits SARS-CoV-2 infection. CBD and its metabolite, 7-OH-CBD, but not congeneric cannabinoids, potently block SARS-CoV-2 replication in lung epithelial cells. CBD acts after cellular infection, inhibiting viral gene expression and reversing many effects of SARS-CoV-2 on host gene transcription. CBD induces interferon expression and up-regulates its antiviral signaling pathway. A cohort of human patients previously taking CBD had significantly lower SARS-CoV-2 infection incidence of up to an order of magnitude relative to matched pairs or the general population. This study highlights CBD, and its active metabolite, 7-OH-CBD, as potential preventative agents and therapeutic treatments for SARS-CoV-2 at early stages of infection.
Don’t get me wrong. I’ve been trying to stay positive since 2017 but it only get’s worst and worst. I have five figures invested and been trying to recover at least $15k. No luck yet
Aleafia Health Announces Results of Annual General Meeting Aleafia Health Inc. Tue, June 29, 2021, 8:15 AM EDT·5 min read
ALEAF -5.05% TORONTO, June 29, 2021 (GLOBE NEWSWIRE) -- Aleafia Health Inc. (TSX: AH, OTCQX: ALEAF) (“Aleafia Health” or the “Company”), a global leader in cannabis wellness products and services, is pleased to announce the results of the vote on the election of directors at its annual meeting of shareholders held on June 28, 2021 (the “Meeting”). All seven nominees set out in the management information circular of the Company dated May 20, 2021 were elected to the board of directors (the “Board”) of the Company.
Nominee
Votes in Favour
Votes in Favour as % of Votes Cast
Votes Withheld
Votes Withheld as % of Votes Cast
Lea Ray
50,166,148
88.94%
6,236,810
11.06%
Mark Sandler
50,116,911
88.86%
6,286,047
11.14%
Loreto Grimaldi
50,186,704
88.98%
6,216,254
11.02%
Luciano Galasso
50,558,413
89.64%
5,844,545
10.36%
Carlo Sistilli
50,541,623
89.61%
5,861,335
10.39%
Michael LeClair
50,554,433
89.63%
5,848,525
10.37%
Ian Troop
50,534,824
89.60%
5,868,134
10.40%
Final voting results on all matters will be filed on the Company’s SEDAR profile at www.sedar.com.
The Company welcomes two newly elected independent directors, Ian Troop and Michael LeClair. Mr. LeClair is an experienced director in the for-profit and not-for profit sectors in Canada and strategic advisor with an extensive senior leadership background in corporate finance, private equity and mergers & acquisitions. He currently serves as the chair of the board of independent trustees of Centurion Financial Trust, and as a member of the board and audit committee chair of a publicly traded natural food company. Previously, Mr. LeClair was a managing director of the private debt group for TSX listed Integrated Asset Management, a leader in the alternative investment sector with $2.4 billion in assets under management at that time.
- ADVERTISEMENT -
Mr. Troop is a seasoned executive and business leader in the for-profit and not-for-profit sectors in Canada and globally. His career is highlighted by 20 years at Procter & Gamble leading business divisions in Mexico, Poland and North America. He was the CEO of the successful 2015 Parapan American Games hosted in Toronto, which remains the largest sporting event in Canadian history. Mr. Troop was appointed as Operating Advisor to the private equity group of OMERS, one of Canada’s largest pension funds.
Additionally, the Company announces today that Lea Ray and Loreto Grimaldi have indicated their intention to resign from the Board. Their resignations will take effect following a transition period expected to be no more than 30 days following, during which time they will continue as members of the Board.
The Company wishes to thank Ms. Ray and Mr. Grimaldi for their service, leadership and dedication, as two of Aleafia Health’s longest serving board members.
Aleafia Health also announces today that the Board has determined to appoint Jon Pereira as an independent director of the Company. Mr. Pereira will join the Board concurrently with the effectiveness of Ms. Ray and Mr. Grimaldi’s resignations.
Mr. Pereira brings a wealth of operations and executive management experience gained from previously held positions in the electronics manufacturing space and board service. A respected Canadian entrepreneur, he co-founded Olympic Circuits which was later acquired by a U.S. publicly traded company. Mr. Pereira led the integration and continued to serve as president of a key business unit managing over 8000 employees and generating revenue in excess of USD$800 million spanning global markets across North America, Asia and Europe. Throughout his career, Mr. Pereira has led with a strong focus on operational efficiency, cost management and strategic business development. He received a Bachelor of Chemical Engineering from the University of Toronto.
For Investor & Media Relations:
Nicholas Bergamini, VP Investor Relations 1-833-879-2533 IR@AleafiaHealth.com LEARN MORE: www.AleafiaHealth.com
About Aleafia Health:
Aleafia Health is a vertically integrated and federally licensed Canadian cannabis company offering cannabis health and wellness services and products in Canada and with sales and operations in Australia and Germany. The Company operates medical clinics, education centres and production facilities for the production and sale of cannabis.
Aleafia Health owns four significant licensed cannabis production facilities, including the first large-scale, legal outdoor cultivation facility in Canadian history. The Company produces a diverse portfolio of commercially proven, high-margin derivative products including oils, capsules, edibles, sublingual strips, and vapes. Aleafia Health operates the largest national network of medical cannabis clinics and education centres staffed by MDs, nurse practitioners and educators and operates internationally in three continents.
Forward Looking Information
This news release contains forward-looking information within the meaning of applicable Canadian and United States securities laws. Often, but not always, forward-looking information can be identified by the use of words such as “plans”, “expects”, “estimates”, “intends”, “anticipates”, or “believes” or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company or its subsidiaries to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained in this news release. Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information, including risks contained in the Company’s annual information form filed with Canadian securities regulators available on the Company’s SEDAR profile at www.sedar.com. Although the Company believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information and no assurance can be given that such events will occur in the disclosed time frames or at all. The forward-looking information included in this news release are made as of the date of this news release and the Company does not undertake any obligation to publicly update such forward-looking information to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
To follow up, I was up until 3am and had yet to feel the effects. It takes a long time for edibles to hit for me. I slept very well lol! I will try another time, earlier in the day and report on how it feels :)
To follow up, I was up until 3am and had yet to feel the effects. It takes a long time for edibles to hit for me. I slept very well lol! I will try another time, earlier in the day and report on how it feels :)
They are delicious. I am eating them right now. The pretzels are small, about 1 inch square and the caramel in between is creamy and chewy but not tooth grabbing like toffee. There is a slight weed undertone but it is not bad at all. I will let you know what the effect is (if I stay awake that long) I am happy with them. Not good for gluten free folks but the kitchen has other products for them
TORONTO, June 24, 2021 – Aleafia Health Inc. (TSX: AH, OTCQX: ALEAF) (“Aleafia Health” or the “Company”), a global leader in cannabis wellness products and services, today announced the expansion of its cannabis edibles portfolio with the first of its kind of Salted Caramel Pretzel Bites. The new format is now available and sold under the Company’s cannabis edibles brand Bogart’s Kitchen, joining the previously released THC and CBD Soft Chews.
“Today’s launch rounds out what is quickly becoming one of the most diverse and differentiated cannabis product portfolios in the Canadian market. Through identifying gaps in the product marketplace, we have introduced a totally unique form factor that we expect will delight new and experienced cannabis consumers,” said Aleafia Health CEO Geoffrey Benic. “Through the launch of 18 unique product SKUs this calendar year, deployed through multiple channels, our team has demonstrated tremendous executional capabilities. This has resulted in strong sequential growth in the sale of cannabis products this quarter.”
Each pretzel bite features a pair of sweet and salty pretzels sandwiching a creamy cannabis-infused caramel. There are two pretzel bites per package, each containing five mg of THC. The highly differentiated format is designed and produced in the commercial kitchens of Aleafia Health’s product innovation centre in Paris, Ont. Bogart’s Kitchen, part of the Sunday Market brand family, features five distinct brands with differentiated products tailored to specific consumer segments.
For Investor & Media Relations:
Nicholas Bergamini, VP Investor Relations 1-833-879-2533 IR@AleafiaHealth.com LEARN MORE: www.AleafiaHealth.com
About Aleafia Health:
Aleafia Health is a vertically integrated and federally licensed Canadian cannabis company offering cannabis health and wellness services and products in Canada and with sales and operations in Australia and Germany. The Company operates medical clinics, education centres and production facilities for the production and sale of cannabis.
Aleafia Health owns four significant licensed cannabis production facilities, including the first large-scale, legal outdoor cultivation facility in Canadian history. The Company produces a diverse portfolio of commercially proven, high-margin derivative products including oils, capsules, edibles, sublingual strips, and vapes. Aleafia Health operates the largest national network of medical cannabis clinics and education centres staffed by MDs, nurse practitioners and educators and operates internationally in three continents.
Forward Looking Information
This news release contains forward-looking information within the meaning of applicable Canadian and United States securities laws. Often, but not always, forward-looking information can be identified by the use of words such as “plans”, “expects”, “estimates”, “intends”, “anticipates”, or “believes” or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company or its subsidiaries to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained in this news release. Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information, including risks contained in the Company’s annual information form filed with Canadian securities regulators available on the Company’s SEDAR profile at www.sedar.com. Although the Company believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information and no assurance can be given that such events will occur in the disclosed time frames or at all. The forward-looking information included in this news release are made as of the date of this news release and the Company does not undertake any obligation to publicly update such forward-looking information to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
lecorb Wednesday, 06/23/21 12:18:16 PM Re: FUNMAN post# 3162 0 Post # 3163 of 3163 ALEAFIA HEALTH (OTCMKTS:ALEAF) PRICE TARGET AND CONSENSUS RATING 1 Wall Street analysts have issued ratings and price targets for Aleafia Health in the last 12 months. Their average twelve-month price target is $5.81, predicting that the stock has a possible upside of 1,686.04%. The high price target for ALEAF is $5.81 and the low price target for ALEAF is $5.81.
Aleafia Health (OTCMKTS:ALEAF) had its price target cut by Cantor Fitzgerald from $7.06 to $5.81 in a report released on Monday. The firm currently has a “reduce” rating on the stock.
Shares of ALEAF stock traded down $0.00 during trading on Monday, reaching $0.35. 150,800 shares of the company’s stock were exchanged, compared to its average volume of 418,914. Aleafia Health has a twelve month low of $0.29 and a twelve month high of $1.07. The business has a fifty day moving average price of $0.40.
ALEAFIA HEALTH (OTCMKTS:ALEAF) PRICE TARGET AND CONSENSUS RATING 1 Wall Street analysts have issued ratings and price targets for Aleafia Health in the last 12 months. Their average twelve-month price target is $5.81, predicting that the stock has a possible upside of 1,686.04%. The high price target for ALEAF is $5.81 and the low price target for ALEAF is $5.81.
Aleafia Health (OTCMKTS:ALEAF) had its price target cut by Cantor Fitzgerald from $7.06 to $5.81 in a report released on Monday. The firm currently has a “reduce” rating on the stock.
Shares of ALEAF stock traded down $0.00 during trading on Monday, reaching $0.35. 150,800 shares of the company’s stock were exchanged, compared to its average volume of 418,914. Aleafia Health has a twelve month low of $0.29 and a twelve month high of $1.07. The business has a fifty day moving average price of $0.40.
News 
Market Data 
Discover 
AI
